Le Lézard
Classified in: Health
Subject: FDA

Histofluor® Rodent Tissue Slides receive FDA 510(k) clearance


SACRAMENTO, Calif., Jan. 16, 2019 /PRNewswire/ -- Immuno Concepts, a recognized pioneer in innovation of autoimmune diagnostic reagents and instrumentation, is pleased to announce that the United States Food and Drug Administration (FDA), through the 510(k) process, has cleared the Histofluor® Rodent LKS Tissue Slides for manual and Image Navigator® use.

Immuno Concepts' Histofluor® Rodent LKS Tissue Slides receive FDA Approval

The indirect immunofluorescent (IIF) test has long been the preferred method for determination of Anti-Mitochondrial Antibodies (AMA), Anti-Smooth Muscle Antibodies (ASMA), and Anti-Parietal Cell Antibodies.  These autoantibodies are associated with several autoimmune diseases, including Pernicious Anemia or Autoimmune Gastritis, Primary Biliary Cholangitis (PBC), and Autoimmune Hepatitis.  The FDA-Cleared Immuno Concepts' Histofluor® Rodent Tissue Slides are available in both mouse and rat substrates and can be read manually or scanned using the innovative Image Navigator® automated microscope.  The same slides and reagents for the Histofluor® Rodent Tissue Slides are used regardless of whether the slides are read manually or scanned on the Image Navigator®.  There are no "magic ingredients" or special conditions required. The previously FDA-Cleared Image Navigator® is a solution that eliminates the usual tedious labor of the IIF test, while still allowing the laboratory professional to control the interpretation and reporting of these tests. 

"The new Histofluor® Rodent LKS Fluorescent Antibody Test System improves on a diagnostic technique that dates back several decades," commented Eric S. Hoy, Ph.D., SI(ASCP), Chief Scientific Officer of Immuno Concepts.  "The Immuno Concepts kits do not require freezing of any component, including the tissue slides. The available positive controls and titratable controls provide assurance to the user that the patterns seen on the tissues are true evidence of the corresponding autoantibodies. All of the components are ready-to-use and are identical whether the user runs the assay manually or on the Image Navigator®. The Image Navigator® captures multiple images of the three rodent tissues and assembles them into a panoramic view of the well. The user can apply the standard features of the Image Navigator® to enlarge regions of the tissue to examine fine detail and determine the antibody specificity of the fluorescent staining. The new slides and the Image Navigator® together eliminate much of the subjectivity formerly associated with this testing."

In the USA, schedule a demonstration of our solution for total automation of IFA testing by calling 1.800.527.2320 or emailing [email protected]. Outside the US, contact your local Immuno Concepts distributor.

About Immuno Concepts

In 1979, Immuno Concepts pioneered the industry conversion from rodent tissue to HEp-2 cells for detection of ANA's. We followed up with HEp-2000®, the only patented ANA substrate genetically enhanced to improve sensitivity for detection of autoantibodies to the SS-A/Ro antigen. Today, Immuno Concepts has the automated solution for IFA assays, the Image Navigator®. Together, the family of AFT pipetting instruments and Image Navigator® can process a patient sample from collection tube to final result, with better reproducibility and accuracy than manual methods. Come see what's next at http://www.immunoconcepts.com.

Press Contact

Bert R. Williams, III

President of Immuno Concepts

1.800.527.2320

[email protected]

 

Immuno Concepts Logo

SOURCE Immuno Concepts


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: